Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03394365
Title Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Atara Biotherapeutics
Indications
Therapies

Tabelecleucel

Age Groups: senior | child | adult
Covered Countries USA | ITA | FRA | ESP | CAN | BEL | AUT


No variant requirements are available.